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Hepatocellular carcinoma (HCC) is one of the leading cancers in the world 
and this disease is often diagnosed at an advanced stage when potentially curative 
therapies are not feasible. Understanding of the molecular mechanism of HCC is vital 
to develop therapeutical approaches to cure this disease. In recent years, the zebrafish 
has become a popular model to study human diseases, particularly for small molecule 
screening in drug discovery.  
In the current study, we employed two zebrafish tumor models previously 
established in our lab, TO(Myc) and TO(kras) transgenic line, which contain Myc and 
krasv12 oncogenes respectively in a tetracycline-inducible (tet-on) system and 
produced HCC by doxycycline induction. To develop a rapid assay for potential anti-
cancer drug screening, several chemical inhibitors which target a few signaling 
pathways involved in HCC, including MAPK pathway, JAK/STAT pathway, PI3K 
pathway and Myc transcription factor, were selected to treat larvae of the two 
transgenic lines. Following the treatment, liver images were taken and analyzed by 
ImageJ for two-dimensional area quantification followed by cell proliferation analysis 
to further investigate the inhibition effect. 
We observed that some inhibitors such as Stat5In and PD0325901 inhibited 
liver overgrowth in both TO(Myc) and TO(kras) larvae; U0126 was only effective in 
TO(kras) larvae but not in TO(Myc) larvae; LY294002 was able to reduce liver 
enlargement in TO(Myc) larvae but failed to do so in TO(kras) larvae.  
We conclude that inhibition of JAK/STAT pathway or MAPK pathway in 
both Myc and kras mediated oncogenesis suppresses tumor growth, and targeting 
PI3K pathway using LY294002 is a potential means to treat Myc driven oncogenesis.  
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1.1 Introduction of HCC 
 
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer 
death  and it is also one of the top five most common malignant cancers (Ferlay et al., 
2010). As such, the global burden of HCC is very significant and the treatment of 
HCC remains a challenge. HCC often results from chronic liver injury and cirrhosis, 
infections with hepatitis B and hepatitis C, alcoholic liver disease, steatohepatitis, 
hemo-chromatosis, and aflatoxin exposure. 
Due to poor diagnostic technology of this disease, HCC is often diagnosed at 
an advanced stage. Moreover, HCC is highly resistant to conventional systemic 
therapies and only a minority of patients with HCC are eligible to potentially curative 
treatments, such as resection, transplantation and local ablation (Giglia et al., 2010). 
Comparing with traditional chemotherapy, molecular-targeted therapies emerged for 
the treatments of HCC and have advantages of high survival benefits and few side 
effects (Tanaka and Arii, 2009). These targeted agents are designed to hinder and 
delay tumor progression with minor toxicity to normal cells by interfering pathways 
involved in HCC tumorigenesis events, such as cell proliferation, cell differentiation 
and death. Prior to the discovery of the multikinase inhibitor Sorafenib, no effective 
targeted therapy for HCC was available, and the positive results obtained from 
Sorafenib represent a breakthrough in understanding the pathogenesis of HCC and a 
landmark advancement in the way towards HCC curation. Since then, Sorafenib has 
been considered as the standard of care for advanced HCC (Llovet et al., 2008). 
However, the efficacy of Sorafenib is not very high. Indeed, hepatocarcinogenesis is a 
highly complex multi-step process and nearly every pathway involved in 
carcinogenesis is altered to some degree in HCC (Villanueva et al., 2007).  Therefore, 
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a single targeted agent may not achieve complete response in HCC and additional 
agents and novel therapies are urgently needed. One of the main challenges for the 
development of targeted therapies is lacking of comprehensive understanding of HCC 
molecular mechanism.  
1.2 Zebrafish 
 
Animal models are essential in the study of human diseases including HCC. 
Although invertebrate models such as Caenorhabditis elegans and Drosophila are 
often used in studying human disease because of a high degree of molecular 
conservation across the entire animal kingdoms, the invertebrate models often fail to 
reproduce the whole picture of human disease process due to the lack of proper 
physiological context of vertebrates (Giacomotto and Segalat, 2010). Thus, current in-
vivo studies largely rely on mice because of their close resemblance to human. 
However, there are some limitations in the mouse and other mammalian models, e.g. 
high cost, slow development process, small scale production of progeny, etc. In this 
context, the zebrafish (Danio rerio), a complementary vertebrate model system, has 
been drawn into attention in recent years. 
The zebrafish has been developed into an important model organism for both 
developmental and biomedical research over the last two decades. The zebrafish has 
been found to develop almost any tumor type with similar morphology and 
histopathology to human tumors. Although there are obvious differences in the 
physiology of fish and humans that might affect the phenotypic outcome of diseases 
in the zebrafish model, the zebrafish offers several advantages that make it an 
important complement to the mouse model for disease studies: 1) the zebrafish has a 
high fecundity, a pair of zebrafish can produce 100–300 embryos per spawning, 
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making the zebrafish an excellent model for high-throughput small molecule 
screening for preclinical drug discovery and toxicological evaluation; 2) zebrafish 
embryos are transparent, which facilitates direct observation of internal organs by 
light microscopy without killing or manipulating the embryos; 3) embryonic 
development is rapid and embryogenesis is completed in three days after fertilization; 
4) completed genome sequences are available; 5) during organogenesis, zebrafish 
embryos are permeable to small molecules and drugs, providing easy access for drug 
administration and vital dye staining (Kari et al., 2007); 6) zebrafish can conveniently 
be manipulated using well-established genetic and molecular approaches; 7) the 
technology to use fluorescent protein markers in zebrafish is readily available, 
becoming a powerful tool to trace tissue/organs as well as tumors by taking the 
advantage of embryonic and transparent strain, the casper zebrafish (White et al., 
2008). 
1.3 Recent development in chemical screens using zebrafish 
 
The zebrafish has emerged as a rapid model for chemical screens. Comparing 
with high-throughput cell- and molecule-based platforms, the main advantage of 
zebrafish chemical screens is that in vivo efficacy and specificity can be quickly and 
directly assessed in the context of whole zebrafish embryo. Typically, small 
molecules are added to the aquatic environment in which they live, allowing 
absorption into the fish without the need for invasive and time-consuming injection 
(Peal et al., 2010). The zebrafish behaviour and the chemical compounds can be 
examined visually or by microscope. Currently, robotic imaging system coupled with 
analytical computational software is emerged to provide scientists with automatic and 
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high-throughput examination and evaluation of chemical screens in zebrafish 
(Evensen et al., 2010). 
In 2000, Peterson et al. first demonstrated the feasibility of small molecule 
screens for developmental phenotypes with zebrafish embryos by visual examination. 
In this study, a library of 1,100 compounds was screened; several molecules were 
found to affect the development of the central nervous system, cardiovascular system, 
pigmentation and the otic structure (Peal et al., 2010). In a similar study, two other 
groups performed chemical screens for compounds that alter vascular patterns in 
developing eyes (Kitambi et al., 2009, Alvarez et al., 2009). Goessling et al. 
conducted chemical screen on the development and homeostasis of hematopoietic 
stem cells in zebrafish (Goessling et al., 2009). Interestingly, these studies uncovered 
some phenotypes similar to specific diseases. 
Besides focusing on perturbations of developmental processes, investigators 
also use chemical screens to aim at disrupting specific signaling pathways in zebrafish. 
A screen for cell cycle inhibitors has been undertaken in zebrafish embryos by 
Murphey and co-workers (Murphey et al., 2006). Similarly, Torregroza et al. have 
synthesized and screened a small library of compounds that were based on a flavone 
lead known to antagonize TGF-β binding to the TGF-β receptor II (Torregroza et al., 
2009). Recently, Molina et al. have developed an interesting transgenic model to 
search for modulators of the FGF pathway (Molina et al., 2009, Molina et al., 2007). 
In this study, they have screened a library of 5,000 compounds and found that BCI 
bound to and inhibited the Dusp6 phosphatase, preventing ERK dephosphorylation 
and leading to upregulation of FGF.  
Since many zebrafish disease models have been established (Kari et al., 2007), 
chemical screens can be carried out using these zebrafish models to identify 
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compounds that may be useful for treatments of the disease. Recently, in vivo 
chemical screening in zebrafish has been found to be an efficient method to identify 
lead compounds that modulate specific biological processes (Bowman and Zon, 2010). 
For example, in a study using zebrafish in screening small molecules for modulation 
of regeneration process, the chemical compound beclomethasone has been 
demonstrated to block fin regeneration when the glucocorticoid receptor is activated 
during wound healing/blastema formation and knockdown of the receptor restore the 
regenerative ability in the presence of beclomethasone (Mathew et al., 2007). Mutant 
zebrafish with defective BMP signalling have altered dorsal-ventral axis formation 
(Hammerschmidt et al., 1996). Yu and colleagues initiated a large-scale chemical 
screen and found that dorsomorphin could mimic the effects of the BMP-defective 
zebrafish mutants. The compound dorsomorphin is also the first identified chemical 
inhibitor of BMP signaling. Subsequent experiments have revealed dorsomorphin 
plays a role in BMP signaling in iron homeostasis by modestly inhibiting the 
phosphorylation of smads 1, 5, and 8 (Yu et al., 2008). Later, a more potent inhibitor 
of BMP signalling pathway, LDN-193189, has been identified and it has been used 
successfully to treat a mouse model with congenital disorder fibrodysplasia ossificans 
progressive, which is induced by constitutive activation of BMP signalling (Cuny et 
al., 2008).  
Taken together, these studies have demonstrated the application of the 
zebrafish model for high-throughput chemical screening and the zebrafish is emerging 
as an ideal choice to identify therapeutic compounds for human disease. 




The zebrafish is an attractive animal system for modelling human cancers. 
With the well developed transgenic technology, more and more zebrafish cancer 
models relevant to human diseases have been generated, and tumors developed in 
various organs bear striking histological and genetical resemblance to human 
malignancies. Notably, comparative analyses of transcriptome profiles of zebrafish 
and human liver tumors show that human and zebrafish liver tumors indeed share a 
molecular framework that are deregulated during tumorigenesis (Lam and Gong, 2006, 
Lam et al., 2006). 
Strategies to generate liver cancers in zebrafish include chemical carcinogens, 
transplantation and transgenic manipulation.  
It has been demonstrated that zebrafish developed a variety of benign and 
malignant tumors similar to human tumors in histology in various organs after 
exposing to water-borne carcinogens (Spitsbergen and Kent, 2003, Spitsbergen et al., 
2000b, Spitsbergen et al., 2000a). Transplantation of zebrafish tumor cells into wild-
type fish has been performed to evaluate tumor malignancy and to further identify the 
cell of origin of these tumors, as demonstrated in several models, including the T-
ALL (T-cell acute lymphoblastic leukemia), melanoma, and ERMS(Embryonal 
rhabdomyosarcoma) models (Langenau et al., 2007, Langenau et al., 2003). Very 
recently, Marques and colleagues implanted primary human tumour cells in the 
zebrafish and demonstrate invasiveness and metastatic behaviour in zebrafish liver 
(Marques et al., 2009). 
Comparing with carcinogens induction and transplantation for tumor 
formation, the advantages of using transgenic approaches to develop cancer models in 
zebrafish are obvious. Especially, generating transgenic zebrafish has been greatly 
facilitated by transposon technology due to their relative ease of manipulation and 
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high germ-line transmission efficiency. These transposon based methods successfully 
used in the zebrafish include maize Ac/Ds system (Emelyanov et al., 2006), Tol2 
system and Sleeping Beauty system (Kawakami, 2005). In addition to the transposon 
techniques, many tissue-specific promoters have been demonstrated in zebrafish that 
can faithfully reproduce the expression pattern of the endogenous gene to turn on a 
transgene in a particular tissue to facilitate and provide tight spatial and temporal 
regulation of transgene expression (Kawakami et al., 2004, Parinov et al., 2004, 
Emelyanov et al., 2006, Yoshida et al., 2010). 
Several works have demonstrated that overexpression of a single oncogene 
under a strong tissue-specific promoter is sufficient to lead to histologically and 
molecularly validated tumors in transgenic zebrafish (Langenau et al., 2003, Park et 
al., 2008, Sabaawy et al., 2006, Yang et al., 2004). Among the target pool of 
oncogenes, KRAS and Myc are highlighted here because they are two critical 
components for normal cell growth control. 
KRAS is a member of RAS superfamily, a protein superfamily of small 
GTPases. KRAS is activated in many signalling cascades. Moreover, KRAS is one of 
the most frequently activated oncogenes in human cancers, with 17–25% of all human 
tumors harboring an activating mutation in KRAS. In particular, mutations at the 
codon 12 lead to a constitutively active form of KRAS that promotes uncontrolled cell 
proliferation in most types of human tumors (Downward, 2003). Approximately 7% 
of human liver cancers carry activating mutation of this gene (Schubbert et al., 2007).  
Myc is an oncogene coding for a transcription factor that regulates cell cycle, 
cell growth, differentiation, apoptosis, transformation, genomic instability, and 
angiogenesis (Oster et al., 2002). Alterations in the level of Myc expression or protein 
structure are associated with many malignancies in humans and animals. Additionally, 
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Myc has been shown to be one of the most frequently deregulated oncogenes in 
human cancers. Increased expression of Myc has been detected both in experimentally 
induced hepatocellular carcinoma in rodents and in primary human liver tumors, 
confirming its involvement in liver tumorigenesis (Buendia, 2000). 
Our lab has used a Tet-on system to generate transgenic zebrafish to express 
krasv12 or cMyc under a liver-specific fabp10 (fatty acid binding protein10) promoter 
(Gong et al., 2011 and unpublished data). Liver tumor was observed in all transgenic 
lines by doxycycline (Dox) induction in a dosage-dependent manner. These tumors 
can be induced at any developmental stages from juvenile to adult with histological 
examination diagnosed mainly as adenoma at early stage and carcinoma at late stage. 
Interestingly, the induced liver tumors were regressed to normal liver upon removal of 
doxycycline. These transgenic tumor models are convenient for investigation of 
carcinogenesis and future anti-cancer drug screening. Very recently our lab has also 
generated a stable in vivo liver cancer model by constitutive expression of oncogenic 
krasv12 in the liver using transgenic zebrafish under the same fabp10 promoter 
(Nguyen et al., 2011, Nguyen et al., 2012). In this study, it has been found that a high 
level of krasv12 expression is necessary to initiate liver tumorigenesis, which 
progressed from hyperplasia to benign and malignant tumors with histological 
diagnosis of zebrafish tumors identified HCC as the main lesion. The potential use of 
these models has been discussed in a review (Huang et al., 2011). 
1.5 Overview of Signaling Pathways Implicated in HCC  
 
During hepatocarcinogenesis, several important cellular signaling pathways 
are altered, including RAF/MEK/ERK pathway, phosphatidylinositol-3 kinase 
(PI3K)/AKT pathway, JAK/STAT pathway, etc (Figure 1). These pathways are of 
10 
 
interest from a therapeutic perspective, because targeting them may help to reverse, 
delay or prevent liver tumor development. 
1.5.1 MAPK pathway 
 
Mitogen-activated protein kinases (MAPKs) compose a superfamily of protein 
kinases whose function and regulation has been highly conserved in regulating cell 
growth, division and death. Multicellular organisms have three well-characterized 
subfamilies of MAPKs, including extracellular signal-regulated kinase (ERK) or 
MAPK, c-Jun N-terminal kinase, and p38 (Hommes et al., 2003). The ERK or MAPK 
subfamily is considered the ‘classical’ MAPK signaling pathway and consists of a 
MAPK (such as ERK1 and ERK2), a MAPK kinase (MAPKK, such as MEK1 and 
MEK2) and MAPKK kinase (MKKK). The MAPK signaling pathway is activated in 
many human tumors, mediating tumor growth, progression, and metastasis, and is 
therefore an attractive target for novel, molecularly targeted therapies (Sebolt-Leopold 
and Herrera, 2004, Solit et al., 2006). 
 
1.5.2 JAK/STAT pathway 
 
The janus kinases (JAKs) and their downstream signal transducers and 
activators of transcription (STATs) comprise a remarkably direct signaling pathway 
activated by cytokines and growth factors. There are seven STATs (Stats 1, 2, 3, 4, 6, 
and two Stat5 genes) in mammals. The seven STATs act as signaling components 
between the plasma membrane and the nucleus and as transcription factors with 
specific DNA binding ability in the nucleus. JAK/STAT pathway plays a critical role 
in cell growth, differentiation, apoptosis and immune response (Michael, 2002). As 
such, it is not surprising that JAK/STAT pathway plays a role in oncogenesis. 
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1.5.3 PI3K/AKT pathway 
 
The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of 
intracellular lipid kinases that phosphorylate the 3′-hydroxyl group of 
phosphatidylinositol and phosphoinositides. This reaction leads to the activation of 
many intracellular signaling pathways that modulate a wide range of cellular activities, 
including cell survival and growth, metabolic control, vesicle trafficking, cytoskeletal 
rearrangement and migration. PI3K signalling pathway is one of the most highly 
mutated systems in human cancers, underscoring its central role in human 
carcinogenesis (Markman et al., 2010). PI3K controls cell growth, proliferation, and 






Figure 1. An overview of signal transduction pathways. (Adapted from (Hanahan and 
Weinberg, 2000)) In the current study, MEK, PI3K, Stat5 and Myc are selected for 
inhibitors’ targets.  
1.6 Main objectives and significance of the study 
 
Understanding of the pathogenesis of HCC and advances in targeted molecular 
therapies provide new hope for treating this disease. Although the discovery of 
Sorafenib has opened the area of exploration of other molecular-targeted agents for 
HCC, it is still a long road to fight the disease. Therefore, we are motivated to search 
for additional therapies for HCC and to expand the knowledge of understanding the 
disease. 
Currently, the zebrafish has been used as a popular model to study human 
diseases and it is also a favorable in vivo system for small molecule screening. With 
the rapid development of advanced imaging system and analytical computational 
software, high-throughput chemical screens administrated in zebrafish embryos have 
a great advantage. This prompts us to explore the potential of chemical screening in 
zebrafish for anti-cancer drug discovery. Plus, we have established several transgenic 
zebrafish tumor models which have been well characterized to show similar histology 
and pathology to human HCC. Hence, we intend to utilize these transgenic tumor 
larval zebrafish for our current study.  
Firstly, we selected several inhibitors targeting critical HCC molecular 
signalling pathways in hepatocarcinogenesis. Then transgenic larval fish were treated 
by these inhibitors in the presence of the doxycycline inducer. At the end of treatment, 
fish were taken images for quantitative analysis, followed by analysis in histology, 
immunohistochemistry and western blotting validation. We aimed to see whether 
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those inhibitors were able to reverse the phenotype of early tumorigenesis in the 
larvae after exposure to inhibitors. From this project, we hope to investigate the 
molecular mechanisms underlying the HCC development as well as to establish a 
feasible and rapid assay for development of a drug screening platform using our 











2.1 Zebrafish husbandry 
Zebrafish were maintained in the aquarium room at the Department of 
Biological Sciences, National University of Singapore. According to the method 
described (Westerfield, 1994) and in compliance with Institutional Animal Care and 
Use Committee (IACUC) guidelines. Embryos were staged according to the 
description by Kimmel et al. (1995) and presented in hours post fertilization (hpf) or 
days post fertilization (dpf). 
2.2 TO(Myc), TO(kras) and Lipan transgenic zebrafish 
Tg(fabp10:TA; TRE:Myc; CK:RFP) transgenic line and Tg(fabp10:TA; 
TRE:krasV12-GFP) line, known as TO(Myc) and TO(kras) respectively, were 
established by our lab previously, in which mouse cMyc and kras are conditionally 
expressed only in the liver upon doxycycline (Dox) induction respectively. We would 
like to simplify them as cMyc and kras transgenic fish respectively hereafter for 
convenience. Different reporter genes are used in the two lines, skin RFP expression 
serves as an indicator for cMyc positive fish while liver shows GFP expression in 
positive kras fish because of the expression of GFP-kras fusion protein. 
Tg(LFABP-RFP;ElaA-GFP), known as Lipan line, is a double transgenic line 
to express RFP and GFP in the liver and exocrine pancreas respectively from 3 dpf 
(Korzh et al., 2008). In this line, zebrafish start to show RFP and GFP in liver and 
pancreas respectively at 3dpf.  
2.3 Mating of zebrafish 
To facilitate the observation of liver in cMyc fish, cMyc fish were crossed with 
Lipan fish to have cMyc/Lipan double transgenic fish in which liver showed RFP and 
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skin showed RFP fluorescence. For kras line which shows GFP expression in liver in 
the presence of Dox, kras fish were crossed simply with wild-type fish. Moreover, 
since kras fish liver shows no fluorescence in the absence of Dox induction, Lipan 
fish were used to serve a liver size control for exposure to vehicle or inhibitor alone. 
For fish mating, in the afternoon of the previous day for collecting embryos, 5-
10 pairs of male and female zebrafish were placed in mating tanks separately into two 
compartments separated by a divider. The next morning, the divider was removed to 
allow the fish to mate. And embryos were collected. Embryo quality was also checked 
and only healthy embryos were kept before starting the treatment. 1-phenyl-2-thiourea 
(PTU) was added into fish water to inhibit pigmentation before 24 hpf at a final 
concentration of 0.003% (w/v). 
2.4 Timing of exposure to chemicals 
According to published literatures (Zhong and Lin, 2011) and our own 
experience, the earlier the embryos are exposed to chemicals, the higher the death rate 
and side-effects. Moreover, the chorion outside the embryo would affect the 
absorption of some chemicals in the water. As the majority of zebrafish embryos 
would hatch out by 3 dpf, chemicals were added to embryos at 3 dpf to minimize 
undesirable embryonic death and side-effects.  
2.5 Doxycycline induction effect on cMyc and kras transgenic fish 
2.5.1 Survival curve assay by Dox 
Embryos were placed into 6-well plates with a density of 15-20 embryos per 
well. Doxycycline (purchased from sigma) was dissolved in egg water to make stock 
solution. The stock solution was then dispensed in egg water to different final 
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concentrations (Table 1 and Table 2). Treatment was started at 3 dpf and stopped at 7 
dpf or 8 dpf. Solutions were changed every two or three days depending on the water 
quality. The survival number was monitored every day from the beginning of the 
treatment to the end. Based on the survival number, the survival curve was generated. 
Treatment should be kept in dark to avoid Dox lost of function.  
2.5.2 Dox induction treatment 
Zebrafish embryos were distributed into 5.5-cm petri dish with a density of 
60-80 embryos per dish. At 3 dpf, embryos were treated with Dox at different 
concentrations, the same as that in ‘Survival curve assay by Dox’. On the next day, 
cMyc positive or kras positive fish were screened under a fluorescent microscope 
(Olympus). After screening, fresh chemical solution were added to continue 
treatments until 7 dpf. The fish survival and water quality were monitored every day. 
Basically, more than 25 embryos were obtained from screening for each treatment 
group. 
2.6 Inhibition effect of different inhibitors on cMyc and kras fish 
2.6.1 Survival curve analysis 
Experimental procedure is the same as in ‘Survival curve assay by Dox’. 
Chemicals were dissolved in DMSO and concentrations used are listed in Table 1 and 
Table 2 for cMyc and kras fish respectively. 
2.6.2 Inhibition treatment 
Zebrafish embryos were placed into 5.5-cm petri dish with a density of 60-80 
embryos per dish. In our experiment, ‘Dox only’ was set as the positive control, 
‘inhibitor only’ and ‘0.1% DMSO’ as two negative control groups, and 
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‘inhibitor+Dox’ as the experimental group. In ‘Dox only’ group, 0.1% DMSO was 
used as vehicle. Treatments were started at 3 dpf and last until 7 dpf. 
2.7 Photography 
At the end of treatments, 15-20 treated fish of each group were randomly 
chosen from the pool of fish for imaging. Fish were firstly anesthetized in 0.05% 
phenoxyethanol and immobilized in 3% methylcellulose. The fish left-side was faced 
up. Each fish was photographed in both bright field and fluorescent view using an 
Olympus stereo microscope. Exposure time was fixed at 5 ms and 100 ms for RFP 
and GFP, respectively.  
2.8 Image analysis and statistical analysis 
Images of treated fish were analyzed by ImageJ program (Figure 2). Firstly, 
colour image of fluorescent liver was converted to grayscale, measurement scale was 
set as 1 µm/0.76 pixel. The threshold was adjusted until all the fluorescent liver area 
was covered. Finally area of entire liver was calculated. The outline of entire liver was 
automatically drawn and the outlined area was calculated by ImageJ program. The 
measurement was further analyzed in Microsoft Excel 2007. Error bars are used to 
indicate ‘Standard Error’ throughout the thesis. 
According to the Empirical Rule (also known as 68-95-99.7 rule) in statistics 
(Page111 in Kirkup, 2002), in a normal probability distribution, 95% (confidence 
interval) of the values would lie within 1.96 standard deviations (SD) of the mean.  z 
score represents the distance between the raw score and the population mean in units 
of the standard deviation. z is negative when the raw score is below the mean, positive 
when above. z=(x-µ)/σ, where x is a raw score; µ is the mean of the population; σ is 
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the standard deviation of the population. Thus, those values with ‘z score less than -
1.96 or greater than 1.96’ are considered as outliers which are unusually small and 
large in the data set and removed from the raw data set. Statistical analysis was 
performed by a Student’s t-test for direct comparisons between control and 
experimental groups. P values of <0.05 were considered statistically significant.  
 
 
Figure 2. Image analysis with ImageJ program. (A) (B) Fluorescent liver in 
larval fish. (C) After conversion to grayscale. (D) After threshold adjustment, the 
liver area was highlighted and converted to black area. The black area was further 
selected and area was measured. 
 
2.9 Criteria for ‘effective inhibitor’ 
If treated fish showed statistically significant difference (P value<0.05) in 
either liver area or proliferating cell number in ‘inhibitor+Dox’ group versus ‘Dox’ 
group, the inhibitor was considered to be effective.  
2.10 Analysis of cell proliferation 
2.10.1 Cryosection of zebrafish liver 
Selected treated fish were fixed in 4% PFA/PBS at room temperature (RT) for 
one hour (hr) and then at 4oC for overnight. The next day, fixed fish were washed 
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with PBS for 20 minutes (min) and then transferred into molten 1.5% bactoagar/5% 
sucrose. The block was then transferred into 30% sucrose solution and incubated at 
4oC overnight. Subsequently, a layer of tissue-freezing medium (Reichert-Jung, 
Germany) was placed on the pre-chilled tissue holder and the block was then placed 
on top of this layer. The block was then coated with one layer of tissue-freezing 
medium, and frozen in liquid nitrogen until the block solidified completely. The 
frozen specimen was placed into -30oC microtome for 2 hrs to be equilibrated. 
Perform sections at 10-mm thickness. Sections were placed on Superfrost Plus slides 
(Fisher, USA). The frosted slides were dried on a 42oC hot plate for about 2 hrs. 
Afterwards, the sections were kept at -80oC or immediately proceed to further 
procedures.  
2.10.2 Detection of proliferating cell in zebrafish liver by PCNA staining 
The sections were fixed briefly with 4% PFA/PBS for 10 min and washed 3 
times in PBS for 5 min each. Samples were blocked using 5% BSA containing 1% 
H2O2 at RT for 1-2 hrs and washed with PBST (PBS+0.1% Tween 20) for 15 min. 
The sections were then incubated at 4oC for overnight with PCNA primary antibody 
(1:1000 in 2% BSA). After removing the primary antibody, sections were briefly 
washed twice followed by 2-3 times for 10 min each with PBST. Sections were 
incubated with secondary antibody (Dako Kit) conjugated with HRP at RT for 30 
min-1 hr and washed with PBST 3 times for 20 min each. Then sections were applied 
with DAB (10 µl) +substrate buffer (1 ml) (1:100 dilution) for a few minutes for color 
development. The color development was monitored carefully under a microscope 
and stopped as soon as possible once it was well-stained. Reaction was stopped by 
washing with PBS for 3 times (10 min each). The nuclei were stained with Hoechst 
(1:1000 in PBS) for a few minutes and followed by PBS washing for 3 times (10 min 
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each). Finally, the sections were mounted in Flurosave medium (Calbiochem) and 
kept in the dark at RT to dry for 2 hrs and proceeded to photography or kept in -20ºC. 
2.10.3 Image analysis and statistical analysis 
Stained slides were observed under a converted microscope (Zeiss, Germany). 
Images were taken using 40X objective. Raw images were processed and analyzed by 
Adobe Photoshop CS4 and ImageJ program. The proliferating cell number and liver 
area were measured by ImageJ program. The measurement data was further processed 
by Microsoft Excel. Use the value of (proliferating cell/nm2) to evaluate the 
proliferation status of each group fish liver. Statistical analysis was performed by a 
Student’s t-test for direct comparisons between control and experimental groups. P 
values of <0.05 were considered statistically significant.    
2.11 Inhibitors used in the study 
All inhibitors used in the study are listed in Table 3. To make it succinct, we 
would like to simplify ‘Stat5 inhibitor, N’-((4-Oxo-4H-chromen-3-yl) methylene) 




Table 1. Chemicals concentrations used in survival curve and inhibition 
treatment--kras fish 
Chemicals Testing concentrations (survival curve) 
Con.(inhibition 
treatment) 






µg/ml  10 µg/ml 








µM 5 µM 








nM 150 nM 
U0126 1 µM 2 µM 5 µM 10 µM 
20 
µM 5 µM 
LY294002 1 µM 2 µM 5 µM 10 µM 
15 
µM 5 µM 
10058-F4 0.5 µM 
0.8 
µM 1 µM 2 µM  0.5 µM 
 
Table 2. Chemicals concentrations used in survival curve and inhibition 
treatment--cMyc fish 
Chemicals Testing concentrations (survival curve) 
Conc.(inhibition 
treatment) 


















U0126 1 µM 5 µM 10 µM  
2  µM 




10058-F4 0.5 µM 
0.8 
µM 1 µM 2 µM 
0.8 µM 
 
Table 3. List of inhibitors 
Name target company 
10058-F4 cMyc sigma 
PD0325901 MEK1/2 tocris 
U0126 MEK1/2 calbiochem 
LY294002 PI3K promega 
Stat5inhibitor,   N’-((4-Oxo-4H-chromen-3-yl) 










3.1 Dose-dependent induction of liver hyperplasia by doxycycline in cMyc and 
kras fish 
 
cMyc transgenic zebrafish were exposed to a range of Dox concentrations for 
consecutive four days from 3 dpf to 7 dpf to establish the appropriate concentration 
used for subsequent inhibition experiment. In all tested concentrations, we found 
nearly no mortality (Figure 3A) and thus the majority of fish could tolerate all 
concentrations tested. The fish livers showed enlargement in a dose-dependent 
manner comparing with the water control group (Figure 3B). Statistical analysis 
showed that in cMyc fish, liver area from Dox of 30 µg/ml and 40 µg/ml group were 
significantly different from the water control group (Figure 3C). In consequence, 30 







Figure 3. Dose-dependent induction of liver hyperplasia by Dox in cMyc 
fish. (A) Survival curve of cMyc fish under different concentrations of Dox. (B) 
Representative liver images from each treated group showing RFP fluorescence 
in a dose-dependent manner. Scale bar: 0.2 mm. (C) Quantification of liver area 
from fish under different concentrations of Dox compared to control (* 0.01<p 
















































Kras transgenic zebrafish were also exposed to a range of Dox concentrations 
for consecutive four days from 3 dpf to 7 dpf to establish the appropriate 
concentration used for subsequent inhibition experiment. There was no death 
observed in all tested concentrations of Dox (Figure 4A), and the fish liver showed 
enlargement in a dose-dependent manner comparing with the water control group 
(Figure 4B). Statistical analysis showed that in kras fish, liver area from all induction 
groups was significantly larger than the control group (Figure 4C). However, based on 
our observation, in 5 µg/ml of Dox induction group, the average fluorescence 
intensity of kras fish liver was not as strong as that in 10 µg/ml of Dox induction 
group. Therefore, 10 µg/ml of Dox was used for liver hyperplasia induction in kras 








Figure 4. Dose-dependent induction of liver hyperplasia by Dox in kras fish. 
(A) Survival curve of kras fish under different concentrations of Dox. (B) 
Representative liver images from each treated group showing RFP and GFP 
fluorescence in Lipan control and other Dox treated kras fish respectively. Scale 
bar: 0.2 mm. (C) Quantification of liver area from fish under different 


















































To compare the induced liver area in cMyc and kras fish under the same 
concentration of Dox, we calculated the ratio of the liver area of induction groups 
over the control groups in both cMyc and kras lines. The result is shown in Figure 5. 
The graph provides the evidence that the induced liver in kras fish was much higher 
than those in cMyc fish under the same Dox concentration, indicating that the kras 
gene may be more potent than the cMyc gene to cause liver hyperplasia. While the 
reason for this difference remains to be investigated, it is plausible to note that kras 
acts at more upstream than cMyc in molecular network for hepatocarcinogenesis and 
may have a more pleiotropic effect in activation of many downstream effectors 
leading to tumorigenesis (Figure 1). 
 
Figure 5. Comparison of induced liver area in cMyc fish and kras fish 
under the same concentration of Dox. Number labeled on top of the 
histogram is the ratio of (average liver area of induced fish/average liver area 
of control fish). 5 µg/ml Dox for cMyc fish and 40 µg/ml Dox for kras fish 







































3.2 Inhibitory effect of different pathway inhibitors on cMyc-dependent liver 
hyperplasia 
 
Based on literature research, we selected several chemical compounds that 
potentially inhibit some critical HCC signaling pathways (refer to Material and 
Methods). We applied these inhibitors to our transgenic larval fish, cMyc and kras, 
under the Dox induction. The results are presented in the following sections.    
3.2.1 Stat5 inhibitor 
 
The survival rate of cMyc fish treated by Stat5 inhibitor (Stat5In) was first 
assessed in concentrations ranging from 1 µM to 15 µM. The survival curve showed 
no fish death under concentrations of 5 µM or lower (Figure 6A). Thus, in the 
inhibition experiment, we used 5 µM of Stat5In. The average liver area of 
‘Stat5In+Dox’ treated group was obviously smaller than that of the ‘Dox’ induction 
group (Figure 6B). Statistical analysis showed that the difference of liver area 
between these groups was significant (P value<0.01) (Figure 6C), suggesting that 
Stat5In was able to inhibit liver overgrowth in cMyc fish under Dox induction. In 
addition, there was no difference in the liver area from the ‘Stat5In’ group and the 
‘DMSO’ control group, suggesting that this inhibitor may not affect the normal liver 










Figure 6. Effect of Stat5In on liver hyperplasia in cMyc fish. (A) Survival 
curve of cMyc fish under different concentrations of Stat5In, 0.1% DMSO, 1 
µM, 5 µM, 10 µM, 15 µM. (B) Representative liver images from treated and 
untreated fish showing RFP fluorescence. Stat5In: 5 µM. Scale bar: 0.2 mm. 
(C) Comparison of liver area from ‘DMSO’, ‘Stat5In’, ‘Dox’ and 
‘Dox+Stat5In’ group. Liver from ‘Dox+Stat5In’ showed significant decrease 
in area comparing to ‘Dox’ group (P value<0.01). *: P value <0.01. Stat5In: 
5 µM. Because the inhibition treatments of the three inhibitors were 
performed concurrently, the ‘DMSO’ and ‘Dox’ groups data are shared in 







































3.2.2 MEK1/2 inhibitor: PD0325901 
 
The tolerability of PD0325901, an inhibitor of MEK1/2 of MAPK pathway on 
cMyc fish was assessed at concentrations 50 nM, 100 nM and 200 nM with 0.1% 
DMSO as vehicle control. The survival curve showed that no fish died under 
concentrations of lower than 200 nM (Figure 7A). Thus, in the inhibition experiment, 
we used 150 nM PD0325901. The average liver area of ‘PD0325901+Dox’ treated 
group was significantly smaller than that of the ‘Dox’ induction group (Figure 7B). 
Statistical analysis showed that the difference of liver area between these two groups 
was significant (Figure 7C), suggesting that PD0325901 was able to inhibit liver 











Figure 7. Effect of PD0325901 on liver hyperplasia in cMyc fish. (A) 
Survival curve of cMyc fish under varying concentrations of PD0325901, 0.1% 
DMSO, 50 nM, 100 nM, 200 nM. (B) Representative liver images from 
treated and untreated fish showing RFP fluorescence. PD0325901: 150 nM. 
Scale bar: 0.2 mm. (C) Comparison of liver area from ‘DMSO’, 
‘PD0325901’, ‘Dox’ and ‘PD0325901+Dox’ group. Liver from 
‘PD0325901+Dox’ showed significant decrease in area comparing with ‘Dox’ 
group (*, P value <0.01). PD0325901: 150 nM. Because the inhibition 
treatments of the three inhibitors were performed concurrently, the ‘DMSO’ 






































3.2.3 MEK1/2 inhibitor: U0126 
 
The tolerability of U0126, another inhibitor of MEK1/2 of MAPK pathway, 
on cMyc fish was tested at concentrations of 1 µM, 5 µM and 10 µM, with 0.1% 
DMSO as vehicle control (Figure 8A). Based on the survival curve, we used 5 µM of 
U0126 in the following inhibition experiment. However, many fish from ‘5 µM 
U0126+Dox’ group died just after the day of starting chemical exposure. Thus, we 
lowered the concentration of U0126 to 2 µM. As shown in Figure 8B, the inhibition 
effect of U0126 was not obvious and further statistical analysis showed that there was 
an increased trend although not statistically significant in the average liver area of 
‘U0126+Dox’ comparing with that of the ‘Dox’ induction group (Figure 8C), 
indicating that U0126 at the dosage of 2 µM did not inhibit liver overgrowth in cMyc 
fish. We suspected that the concentration of U0126 (2 µM) applied was not high 
enough to be effective; however, slightly higher concentration (5 µM) sometimes 
caused an unacceptable high mortality in treated fish. Therefore, the U0126 
experiment may not be conclusive for the cMyc-dependent hyperplasia. Interestingly, 
single treatment with U0126 appeared to cause liver enlargement and double 







Figure 8. Effect of U0126 on liver hyperplasia in cMyc fish. (A) Survival 
curve of cMyc fish under different concentration of U0126, 0.1% DMSO, 1 
µM, 5 µM, 10 µM. (B) Representative liver images from treated and 
untreated fish showing RFP fluorescence. U0126: 2 µM. Scale bar: 0.2 mm. 
(C) Comparison of liver area from ‘DMSO’, ‘U0126’, ‘Dox’ and 
‘Dox+U0126’ groups. Liver from ‘Dox+U0126’ showed no difference in 
area comparing to ‘Dox’ group. *: significant difference from ‘DMSO’ 
control, P value <0.01. U0126: 2 µM. Because the inhibition treatments of 
the three inhibitors were performed concurrently, the ‘DMSO’ and ‘Dox’ 








































3.2.4 PI3K inhibitor: LY294002 
 
The tolerability of LY294002 on cMyc fish was tested in concentrations of 1 
µM, 5 µM, 10 µM, 15 µM in the presence of 0.1% DMSO (Figure 9A). Based on the 
survival curve, we used 2 µM LY294002 in the following inhibition experiment. As 
shown in Figure 9B, the inhibition effect of LY294002 was very evident and 
statistical analysis showed that there was a significant decrease in the average liver 
area of ‘LY294002+Dox’ comparing with that of the ‘Dox’ induction group (Figure 
9C). It is also interesting to note that most of fish from ‘LY294002’ group showed 
larger liver than those from ‘DMSO’, and this difference was statistically significant 
(*, P value<0.01) (Figure 9C). Nevertheless, LY294002 appeared to be a potent 





   
 
Figure 9. Effect of LY294002 on liver hyperplasia in cMyc fish. (A) 
Survival curve of cMyc fish under various concentrations of LY294002, 0.1% 
DMSO, 1 µM, 5 µM, 10 µM, 15 µM. (B) Representative liver images from 
treated and untreated fish showing RFP fluorescence. LY294002: 2 µM. 
Scale bar: 0.2 mm. (C) Comparison of liver area from ‘DMSO’, ‘LY294002’, 
‘Dox’ and ‘LY294002+Dox’ groups. Liver from ‘Dox+LY294002’ showed 
significant difference in area comparing with ‘Dox’ group (*, P value <0.01). 













































3.2.5 cMyc inhibitor: 10058-F4 
 
To assess the tolerability of 10058-F4, a specific inhibitor of cMyc, on cMyc 
fish, we set several concentrations, 0.5 µM, 0.8 µM, 1 µM, 2 µM (Figure 10A). Based 
on the survival curve, 0.5 µM and 0.8 µM were selected for the inhibition experiment. 
We found that the inhibition effect in 0.5 µM was not as obvious as that in 0.8 µM. In 
consequence, we used 0.8 µM 10058-F4 to repeat the inhibition experiment. Results 
were shown in Figure 10B. Statistical analysis showed that there was no significant 
difference between ‘10058-F4+Dox’ and ‘Dox’ group based on the average liver area 
(Figure 10C). However, the concentrations used in our experiment were much lower 
than those used in cell culture treatment experiment, thus, it is suspected that the low 
efficacy of 10058-F4 was due to the tolerability of this chemical and it is hard to make 
a conclusion here that whether this inhibitor is effective in treating cMyc-dependent 







Figure 10. Effect of 10058-F4 on liver hyperplasia in cMyc fish. (A) 
Survival curve of cMyc fish under different concentrations of 10058-F4. (B) 
Representative liver images from treated and untreated fish showing RFP 
fluorescence. 10058-F4: 0.8 µM. Scale bar: 0.2 mm. (C) Comparison of 
average liver area from ‘DMSO’, ‘10058-F4’, ‘Dox’ and ‘Dox+10058-F4’ 
groups. *: extremely significant difference from ‘DMSO’ control, P value 















































3.2.6 Proliferation analysis on liver from treated cMyc fish 
 
To further confirm the inhibitory effects of different inhibitors on treated cMyc 
fish, we performed immunohistochemistry on liver cryostat sections against PCNA 
antibody. As shown in Figure 11, the proliferating cells in ‘Stat5In+Dox’, 
‘LY294002+Dox’, ‘PD0325901+Dox’ treated fish were obviously less than those in 
Dox treated fish, and quantification analysis showed that the difference from the ‘Dox’ 
group was significant for the ‘Stat5In+Dox’ and ‘LY294002+Dox’ groups, indicating 
that Stat5In and LY294002 effectively functioned in inhibiting the liver cell 
proliferation in cMyc fish. On the other hand, although ‘PD0325901+Dox’ did not 
show significantly decreased cell proliferation, PD0325901 still remarkably reduced 
the cMyc-mediated hyperplasia in terms of liver area (Figure 7). As for U0126, the 
proliferation analysis shown here combining with previous liver area measurement 
analysis demonstrated that this inhibitor might not be effective in treating cMyc-





Figure 11. Proliferation analysis on liver from treated cMyc fish. (A) PCNA 
staining result. Liver area is outlined by black line. Brown dots indicate the 
proliferating cell nuclei. Stat5In: 5 µM; LY294002: 2 µM; PD0325901: 150 nM; 
U0126: 2 µM. (B) Quantification of proliferating cell from PCNA staining result. a: 
significant difference from ‘DMSO’ control, P value <0.05; b: significant difference 





























3.3 Inhibitory effect of different pathway inhibitors on kras-dependent liver 
hyperplasia 
 
3.3.1 Stat5 inhibitor  
 
The tolerability of Stat5 inhibitor (Stat5In) on kras fish was tested in 
concentrations ranging from 1 µM to 20 µM using 0.1% DMSO as vehicle (Figure 
12A). We selected 2 µM and 5 µM Stat5In in the subsequent inhibition experiment, 
and more than half of the fish at 5 µM survived till the end of the treatment and 
showed more evident inhibition effect than those in 2 µM. So we repeated the 
treatment using 5 µM Stat5In. The average liver area of ‘Stat5In+Dox’ treated group 
was obviously smaller than that of the ‘Dox’ induction group (Figure 12C), and 
statistical analysis showed that the difference of liver area between these two groups 
was significant (P value<0.05). In addition, the liver area of the ‘Stat5In’ group 
showed no difference from the ‘DMSO’ control group, suggesting that this chemical 







Figure 12. Effect of Stat5In on liver hyperplasia in kras fish. (A) Survival 
curve of kras fish under varying concentrations of Stat5In. (B) 
Representative liver images showing RFP and GFP fluorescence in Lipan 
control and treated kras fish. Stat5In: 5 µM. Scale bar: 0.2 mm. (C) 
Comparison of liver area from ‘DMSO’, ‘Stat5In’, ‘Dox’ and ‘Stat5In+Dox’ 
group. Liver from ‘Stat5In+Dox’ showed significant decrease in area 








































3.3.2 MEK1/2 inhibitor: PD0325901 
 
Survival curve of kras fish was first generated to test the tolerability of 
PD0325901 (Figure 13A). In the inhibition experiment, we used 150 nM of 
PD0325901 and we found that most of the liver from ‘PD0325901+Dox’ became 
smaller (Figure 13B); however, based on statistical analysis, the average liver area in 
‘PD0325901+Dox’ treated group was not significantly different from that of ‘Dox’ 
induction group (Figure 13C), which might be due to the big variation in liver area 
among the overall treated population. However, the effect can be obviously achieved 
if increasing the population of treated fish. We also observed some phenotypical 
changes, e.g. yolk shrink, in fish from ‘PD0325901’ control group (pictures not 
shown); however, based on the statistical analysis, the average liver area of the 
‘PD0325901’ group showed no difference from the ‘DMSO’ control group, implying 
this chemical might be a little toxic to the normal development but still can be 







Figure 13. Effect of PD0325901 on liver hyperplasia in kras fish. (A) 
Survival curve of kras fish under different concentrations of PD0325901. (B) 
Representative liver images showing RFP and GFP fluorescence in Lipan 
control and treated kras fish. PD0325901: 150 nM. Scale bar: 0.2 mm. (C) 
Comparison of liver area from ‘DMSO’, ‘PD0325901’, ‘Dox’ and 
‘PD0325901+Dox’ group. *: significant difference from ‘DMSO Lipan’ 










































3.3.3 MEK1/2 inhibitor: U0126 
 
At first, the tolerability of U0126 on kras fish was examined in concentrations 
ranging from 1 µM to 20 µM (Figure 14A). The survival curve showed that most of 
fish can survive until 8 dpf in concentrations of 5 µM or lower. Thus we tried 2 µM 
and 5 µM U0126 in the inhibition experiment, and more than half of the fish in 5 µM 
of U0126 survived till the end of the treatment with more evident inhibition effect 
than that in 2 µM. So we repeated the treatment using 5 µM U0126. Most of fish from 
‘U0126+Dox’ treated group had smaller livers than those from the ‘Dox’ induction 
group (Figure 14B). Statistical analysis showed that there was no significant 
difference of liver area between these two groups (data not shown) before detecting 
and removing the outliers. However, one extremely large value from ‘Dox’ and one 
extremely large value from ‘U0126+Dox’ were detected and removed from the data 
set, and now the statistical result showed that the difference of liver area between 
‘Dox’ and ‘U0126+Dox’ was significant (P<0.05, Figure 14C). Notably, the liver area 
of the ‘U0126’ group was significantly larger than that from the ‘DMSO’ control 
group, suggesting this chemical might induce liver overgrowth in normal fish (Figure 







Figure 14. Effect of U0126 on liver hyperplasia in kras fish. (A) Survival 
curve of kras fish under different concentrations of U0126. (B) 
Representative liver images showing RFP and GFP fluorescence in Lipan 
control and treated kras fish. U0126: 5 µM. Scale bar: 0.2 mm. (C) 
Comparison of liver area from ‘DMSO’, ‘U0126’, ‘Dox’ and ‘U0126+Dox’ 









































3.3.4 PI3K inhibitor: LY294002 
 
LY294002 is an inhibitor of PI3K, and the tolerability of this chemical on kras 
fish was assessed in concentrations ranging from 1 µM to 15 µM (Figure 15A). 
Subsequently, 5 µM was used for the inhibition experiment. Results were shown in 
Figure 15B. Statistical analysis showed that there was no significant difference 
between ‘LY294002+Dox’ and ‘Dox’ in the overall population (Figure 15C). Thus, 
LY294002 was not effective in inhibiting the liver overgrowth in kras fish. It is also 
interesting to note that most of fish from ‘LY294002’ group showed larger liver than 
those from ‘DMSO’, and this difference was statistically significant (*, P value<0.01), 







Figure 15. Effect of LY294002 on liver hyperplasia in kras fish. (A) 
Survival curve of kras fish under different concentrations of LY294002. (B) 
Representative liver images showing RFP and GFP fluorescence in Lipan 
control and treated kras fish. LY294002: 5 µM. Scale bar: 0.2 mm. (C) 
Comparison of liver area from ‘DMSO’, ‘LY294002’, ‘Dox’ and 












































3.3.5 cMyc inhibitor: 10058-F4 
 
10058-F4 is a specific inhibitor of cMyc, and the tolerability of this chemical 
on kras fish was assessed in concentrations 0.5 µM, 0.8 µM, 1 µM and 2 µM (Figure 
16A). Based on the survival curve, 0.5 µM was used for the following inhibition 
experiment. Results were shown in Figure 16B. Statistical analysis showed that there 
was no significant difference between ‘10058-F4+Dox’ and ‘Dox’ (Figure 16C). 
Furthermore, only 57.9% of the fish from ‘10058-F4+Dox’ were statistically 
significantly (P value<0.05) smaller in liver area than that from ‘Dox’ (Figure 16D). 









Figure 16. Effect of 10058-F4 on liver hyperplasia in kras fish. (A) 
Survival curve of kras fish under different concentrations of 10058-F4. (B) 
Representative liver images showing RFP and GFP fluorescence in Lipan 
control and treated kras fish. 10058-F4: 0.5 µM. Scale bar: 0.2 mm. (C) 
Comparison of liver area from ‘DMSO’, ‘10058-F4’, ‘Dox’ and ‘10058-








































3.3.6 Proliferation analysis on liver from treated kras fish 
 
To further confirm the inhibitory effects of different inhibitors on treated kras 
fish, we performed immunohistochemistry on liver cryostat sections against PCNA 
antibody. As shown in Figure 17, the proliferating cells in ‘Stat5In+Dox’, 
‘PD0325901+Dox’ and ‘U0126+Dox’ treated fish are obviously less than those in 
‘Dox’ treated fish, and quantification analysis shows that the difference is significant 
between these ‘inhibitor+Dox’ groups and ‘Dox’ group, indicating Stat5In, 








Figure 17. Proliferation analysis on liver from treated kras fish. (A) PCNA 
staining result. Liver area is outlined by black line. Brown dots indicate the 
proliferating cell nuclei. Stat5In: 5 µM; PD0325901: 150 nM; U0126: 5 µM. (B) 
Quantification of proliferating cell from PCNA staining result. a: significant 
difference from ‘DMSO’ control, P value <0.01; b: significant difference from ‘Dox’, 

































3.4 Comparsion of inhibition efficacy of different inhibitors on liver hyperplasia 
between cMyc and kras fish 
 
In our current work, we used five selected inhibitors to treat two different 
transgenic tumor lines, cMyc and kras, under the induction of Dox. For different 
inhibitors, we got different inhibition effect. Since in these two transgenic lines, the 
oncogenesis events are mediated by two different oncogenes, the signaling pathways 
involved are obviously different. We would like to sum up the similarities and 
differences between the two lines and the difference of all inhibitors (Table 4) based 
on the statistical P value (the P value was obtained when student’s t-test was 
performed for comparisons between ‘Dox’ and ‘inhibitor+Dox’ groups). 
From the table in combination with our criteria for selecting an effective 
inhibitor, we can easily conclude that Stat5In, PD0325901 and LY294002 were 





Table 4. Different ‘inhibitors’ efficacy on cMyc and kras fish based on 
statistical analysis on liver area measurement and proliferation assays 
 cMyc kras 
Liver area Proliferation Liver area Proliferation  
Stat5In     
PD0325901     
U0126     
LY294002    N/D 
10058-F4  N/D  N/D 
The color depth stands for different P value range.  
: P<0.01; : 0.01<P<0.05; : P>0.05. 
: P<0.01; : 0.01<P<0.05; : P>0.05. 










By treating with five selected inhibitors on two transgenic liver tumor 
zebrafish, we have achieved some preliminary and encouraging results as some 
inhibitors indeed inhibit the liver hyperplasia at the early stage of tumorigenesis. Here 
we would like to highlight two important aspects towards this study. Firstly, we have 
developed a plausible method for potential drug screening using larval zebrafish; 
secondly, we obtained some promising data which can be served as a basis for further 
investigation into the molecular mechanism of carcinogenesis.   
4.1 Development of image-based phenotypic analysis in transgenic zebrafish to 
evaluate inhibition effects on liver tumorigenesis 
 
The optical transparency of larval zebrafish combining with the use of 
fluorescent markers under the control of tissue specific promoter provides great 
advantages for in vivo visualization. However, most published works on chemical 
screens in zebrafish mainly based on manual and subjective examination due to the 
lack of feasible methodology for imaging and analysis.  
In our study, we established a methodology that is convenient to assess the 
chemical effects. The treated transgenic fish were anesthetized first and then images 
were taken by a stereo microscope mounted with a camera. The images were later 
processed by ImageJ program (Girish and Vijayalakshmi, 2004). Fluorescent liver 
area of each fish was measured ultimately. The measurement results generated from 
ImageJ were processed by Microsoft Excel where statistics analysis was performed.  
Based on the quantification result, the minute difference in liver area between 
control and inhibitor-treated fish can be analyzed and statistically validated. Therefore, 
comparing with visual scoring basing on optical observation, our methodology is 
more quantitative and objective.  
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However, one limitation of this approach based on two-dimensional 
measurement is that the shape and position of the zebrafish liver are easily affected by 
the position of imaging fish. However, this limitation will be largely overcome by 
measurement of a large number of samples. Compared to a three-dimensional 
measurement that requires more sophisticated and powerful microscope and imaging 
software, the two-dimensional measurement can be easily performed for high 
throughput in order to acquire the trend of the response quickly. Another limitation of 
this approach is that it is still time-consuming and involved user intervention. For 
example, when taking images, the embryos had to be orientated and maintained in the 
same direction and we needed to take images one by one for about 100 fish after each 
treatment. Since it is an acute treatment, keeping the same treatment time is quite 
critical. Therefore, it is better to take images for all the fish simultaneously under an 
automatic imaging device that can scan multi-well plates which unfortunately is not 
available in our lab.       
One study has been published recently on development of an automatic 
imaging system to quantify blood vessel development in embryos treated with 
angiogenesis inhibitors (Vogt et al., 2009). In this study, the images for zebrafish in 
96-well plates are acquired using a high-content reader regardless of embryos 
orientation and without user intervention and later analyzed with artificial 
intelligence-based image analysis method termed Cognition Network Technology 
(CNT) in an automatic manner. This methodology was much more time-saving than 
ours since it is able to take images for all fish simultaneously and it does not require 
the embryos at the same direction when photographed. Admittedly, although the 
image analysis software in their study provides more sophisticated numerical data, it 
is more complicated than ours. Therefore, our methodology is simple and easy. 
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In sum, we utilized transgenic zebrafish and combined the imaging technique 
with the automatic computational software to detect and quantify area of fluorescent 
liver, which provided objective and sensitive analysis result to analyze change in the 
fish morphology. With this approach, we are able to see the effects of inhibitors even 
it is very subtle in liver hyperplasia in larval zebrafish. 
We further anticipate that this quantification method can be applied to other 
purposes, e.g. to evaluate the toxicity of certain chemicals on liver and other organ 
development, body length, neuron and axon development, etc. However, our methods 
seem only limited to static organ morphological change, other dynamical organs such 
as circulation system, are difficult to apply.         
4.2 Insights of inhibition mechanisms underlying different inhibitors on cMyc 
fish and kras fish during tumor development 
4.2.1 JAK/STAT pathway and Stat5 inhibitor 
 
We observed that Stat5In significantly inhibited the liver overgrowth in both 
cMyc and kras transgenic zebrafish, which was also supported by decreased 
proliferating cells in ‘Stat5In+Dox’ fish liver (Figure 11A, B and Figure 17A, B). 
STAT5 regulates the expression of genes, which determine important cellular 
processes, including cell proliferation, apoptosis, differentiation and embryonic 
development and organogenesis. It can promote proliferation and inhibit apoptosis, 
and is overactive in several types of leukemias, e.g. Acute Myelogenous Leukemia 
(AML), Acute Lymphocytic Leukemia (ALL) and Chronic Myelomonocytic 
Leukemia (CMML) as well as in solid tumors, such as breast cancer, uterine cancer, 
prostate cancer, and squamous cell carcinoma of the head and neck (SCCHN) (Wittig 
and Groner, 2005). As inhibition of STAT5 has been shown to suppress cell 
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proliferation and to induce cell apoptosis in certain tumor cells (Demoulin et al., 2000, 
Mohapatra et al., 2003, Xi et al., 2003), it would be desirable to directly inhibit the 
STAT5 protein to help dissect and counteract the role of STAT5 in cancer.  
It has been reported by Muller et al. that a newly discovered nonpeptidic small 
molecule, named chromone-based nicotinoyl hydrazone 1, inhibits activation of 
STAT5 directly by targeting the function of its SH2 domain. They provided evidence 
that the compound selectively inhibited activation of STAT5 in a cancer cell line 
(Muller et al., 2008). Here in our current work, we demonstrate that the 
commercialized Stat5 inhibitor, N’-((4-Oxo-4H-chromen-3-
yl)methylene)nicotinohydrazide, reduces liver hyperplasia in vivo. Thus, targeting the 
transcription factor STAT5 provides a basis for effective cancer treatment in both 
cMyc and kras mediated carcinogenesis. 
This phenomenon can be explained by two aspects. On the one hand, since it 
has been demonstrated that STAT5 induces the expression of Bcl-Xl (Dumon et al., 
1999, Horita et al., 2000), an anti-apoptotic protein, it can be inferred that inhibition 
of STAT5 could suppress the expression of Bcl-Xl, which consequently lead to 
apoptosis and inhibit tumor growth. Another interpretation for this inhibitor effect can 
be made from apoptotic effectors, such as caspases. One study has concluded that 
blocking of STAT5 induced cell death in human prostate cancer is mediated by 
caspase 3 through a caspase 9-dependent mechanism (Ahonen et al., 2003). Further 
studies using western blotting to detect the Bcl-Xl, caspases3 and 9 levels need to be 




4.2.2 MAPK pathway and PD0325901, U0126 
 
MEK1/2 is a component of MAPK pathway. MAPK is a downstream effector 
of RAS and MAPK phosphorylates cMyc, which regulates expression of genes 
involved in cell proliferation and cell apoptosis. Once the MAPK pathway is 
disrupted, cMyc function would be affected. Indeed, inhibition of MEK has the 
potential to prevent the subsequent downstream phosphorylation and activation of 
MAP kinase and consequently induces tumor regression and/or stasis in some 
contexts (Solit et al., 2006, Ji et al., 2007). It has been shown that administration of 
MEK inhibitor helps to prevent development of HCC and increase apoptosis in 
existing HCC tumors in mice (Wentz et al., 2008), and results in dose-dependent 
growth inhibition of HCC xenografts (Huynh et al., 2007). 
Inhibitory activity of U0126 is selective for MEK1/2, and does not inhibit 
other protein kinases like Raf, MEKK, ERK or JNK (Duncia et al., 1998).  The 
specificity of U0126 as a MEK1/2 inhibitor has already been established by many 
studies both in vitro (Murakami et al., 2000) and in vivo (Bedogni et al., 2004),  
including one analysis in zebrafish (Hong et al., 2006). In one study using HCC cell 
line, administration of U0126 blocked ERK phosphorylation, and showed anticancer 
effects through inducing cell cycle arrest, increasing cell apoptosis, and decreasing 
tumorigenecity (Wiesenauer et al., 2004). Additionally, in one study using human 
muscle-derived Rhabdomyosarcoma (RD) cell line and other non muscle-derived 
human tumor cell lines, U0126 was found to induce cMyc de-phosphorylation, 
followed by expression level reduction in cMyc and other cMyc targets, such as 
cyclins E2, A and B and CDK2, all of which are regulators of cell cycle (Marampon 
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et al., 2006), and consequently resulted in blocked oncogenic phenotype in used cell 
lines.  
PD0325901 and U0126 both effectively inhibit MEK activity, but the former 
is more potent than the latter in HCC cells based on the median inhibitory 
concentration lying in the nanomolar range (Ishizaki et al., 2010).Targeting MAPK 
pathway with PD0325901 was shown to decrease HCC growth in vitro and in vivo 
mouse model system by inhibiting proliferation and inducing apoptosis (Hennig et al., 
2010). Moreover, PD0325901 recently emerged to be a new clinical candidate in 
treating cancer (Sebolt-Leopold, 2008). Additionally, inducing angiogenesis is a part 
of event of tumorigenesis (Hanahan and Weinberg, 2011), and PD0325901 has a 
potential role in anti-angiogenesis (Sosman and Puzanov, 2006). Thus we suspect that 
the effect observed for PD0325901 inhibition may be a result of inhibition of both cell 
proliferation and angiogenesis.  
In our study, PD0325901 inhibited liver overgrowth in both cMyc and kras 
fish, supported by decreased cell proliferation (Figure 11A, B and Figure 17A, B), but 
U0126 was effective only in kras fish.  
However, according to other research literatures, U0126 helped to block the 
oncogenic phenotypes (Wiesenauer et al., 2004, Marampon et al., 2006), we can not 
rule out the possibility that U0126 inhibits tumor progression in cMyc fish in a modest 
way due to the low concentration which provided only part suppression of MEK. It is 
also possible that it may regulate other molecules that stimulate the cell proliferation 
or blood vessel growth in fish development, since we observed that U0126 alone-
treated normal fish also had liver enlarged comparing with vehicle-treated control fish.  
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In summary, our test implicated MAPK signaling pathway is activated in both 
cMyc and kras oncogenesis and targeting MAPK pathway could be useful in treating 
HCC. While inhibitor PD0325901 was effective in both cMyc and kras carcinogenesis, 
U0126 was effective in kras carcinogenesis. 
Anti-apoptotic proteins Bcl-Xl and survivin have been shown to be highly 
upregulated in human HCC tissues (Ikeguchi et al., 2002, Watanabe et al., 2002); and 
MEK inhibition by U0126 decreased the expression of these two proteins 
(Wiesenauer et al., 2004), suggesting these two proteins potential playing roles as 
MEK-dependent apoptosis mediators . It might be interesting to perform further 
apoptotic assay and western blot examining the ERK (downstream of MEK) and Bcl-
Xl and survivin so as to better understand the mechanism.  
4.2.3 PI3K pathway and LY294002 
 
Initially, validation of PI3Ks as drug targets has been attempted using 
wortmannin and LY294002, both of which target a broad range of PI3K-related 
enzymes (Arcaro and Wymann, 1993, Wymann et al., 2003). LY294002 is 
competitive for ATP binding site on PI3K, thus leading to the kinase out of function. 
We selected LY294002 in our current study also due to its superior chemical stability. 
Our study showed that LY294002 was able to reduce liver hyperplasia in cMyc fish 
but not in kras fish.  
One study demonstrated that cMyc accumulation was controlled by Ras 
activities either via Raf/ERK pathway or via PI3K/Akt-mediated inactivation of 
Glycogen synthase kinase-3 (GSK-3) activities (Sears et al., 2000). In this study, the 
treatment of PD98059 (an inhibitor of MEK1/2) and Wortmannin (an inhibitor of 
PI3K) impairs the Ras-mediated stabilization of cMyc protein, thus both ERK and 
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PI3K involve in the regulation of cMyc levels. Thus, if PI3K was inhibited, Akt 
activity would be declined and GSK-3 would be activated which subsequently results 
in cMyc protein degradation, which then down regulate the cell proliferation. 
However, on the controversial side, the overexpression of kras results in cMyc 
accumulation via Raf/ERK pathway and may cause subsequent increased cell 
proliferation. Therefore, there must be a competition between the cMyc degradation 
and accumulation under the treatment of PI3K inhibitor LY294002 in kras-dependent 
liver hyperplasia. In our study, the anti-tumor effects of LY294002 in kras fish was 
not achieved, which might be the result of overwhelming accumulation of cMyc; 
another reason might be low concentration of this inhibitor used (5 µM), comparing 
with higher concentration used in other works (50 µM in (Perkinton et al., 2002); 10 
µM in (Nguyen et al., 2012). It is required to look into the protein levels of ERK, Akt, 
GSK-3 and cMyc to determine whether the targeted protein PI3K is inhibited and the 
downstream effectors are affected so as to dig out the mechanism. 
As in cMyc fish, we observed reduced liver enlargement when treated with 
LY294002. The result obtained here seems contradictory to one recent study, where 
elevation of cMyc drives tumors to become independent of PI3K pathway, suggesting 
the cMyc-driven tumors resistant to current PI3K-targeted therapies (Liu et al., 2011). 
As cMyc is a downstream effector of PI3K pathway (Sears et al., 2000), it can be 
hypothesized that cMyc-driven carcinogenesis is independent of PI3K inhibition. Our 
result is not coincide with this hypothesis, thus further investigation into the protein 
level of Akt, GSK-3 and cMyc would be helpful to address this controversy. 
It is also interesting to note that LY294002 alone treated fish also showed 
enlarged liver comparing with control fish. While it is unknown if LY294002 has 
other potential roles in regulating other cellular activities, it is likely that an increased 
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angiogenesis leads to enlarged liver. Arkaitz et al. showed that inhibition of mTOR 
results in activation of MAPK pathway via PI3K-dependent negative feedback loop 
stemming from S6, a downstream effector of mTOR (Carracedo et al., 2008). 
Moreover, a recent study carried out by Anne and colleagues on human umbilical vein 
endothelial cells (HUVEC) demonstrated that on the one hand, mTOR inhibitors 
effectively block mTOR activity and on the other hand increase MAPK 
phosphorylation (Dormond-Meuwly et al., 2011). These works inspire us to 
hypothesize that although LY294002 blocks PI3K activities, it also increases MAPK 
phosphorylation which induces cell proliferation through negative feedback loop. To 
confirm this hypothesis, western blot analysis about the level of S6, ERK and Akt 
proteins and CD31 immunohistochemistry (evaluation of the degree of tumor 
angiogenesis) can be performed to unravel the veil of the mechanism. 
4.2.4 cMyc pathway and 10058-F4 
 
It is known that activation of cMyc contributes to the cancer development. The 
cMyc protein is a transcription factor, plays critical roles in cell proliferation, growth, 
cell cycle progression, genomic stability, differentiation, and apoptosis (Yin et al., 
2003). cMyc contains a basic helix-loop-helix/leucine zipper motif (bHLHZ) that 
drives heterodimer formation with the bHLHZ domain of the Max protein (Amati et 
al., 1993, Henriksson and Luscher, 1996, Oster et al., 2002, Yin et al., 2003). 
Myc/Max heterodimers function by binding E-box DNA (CACGTG) in the target 
gene, thereby regulating transcription. Recent work confirms that Myc inhibitors 
including some small molecules hinder tumor cell growth. One class of small 
molecule inhibitors disrupts the formation of the Myc/Max heterodimer. The 
disruption of the dimer results in inhibition of the transcriptional function of cMyc. 
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10058-F4 is among the first compounds found to disrupt the association between 
cMyc and Max. Gomez-Curet et al. reported that 10058-F4 not only blocked cMyc 
function through the mechanism of cMyc/Max heterodimer dissociation, but also 
decreased cMyc mRNA levels in lymphoma cells (Gomez-Curet et al., 2006). 
In our study, we observed that both cMyc and kras fish showed no obviours 
change in liver enlargement after exposure to 10058-F4, indicating that 10058-F4 by 
inhibiting cMyc failed to fully reduce the liver hyperplasia in both cMyc and kras-
driven carcinogenesis. One of the reasons could be due to the low concentration of 
this inhibitor used in current fish study, only 0.5/0.8 µM which is far lower than those 
used in cell based assay (IC50=60 µM); another reason might be that inhibition of 
cMyc alone may not be sufficient to block tumorigenesis since there are many 
pathways that may lead to tumorigenesis; the third reason for the case in kras-driven 
carcinogenesis may be that the kras-dependent liver carcinogenesis is not via cMyc 
pathway, thus inhibition of cMyc could not help to reverse the kras role in cancer.     
4.3 Major conclusions and findings 
 
In our current work, we employed two transgenic zebrafish tumor models, 
cMyc and kras line, to study the early tumorigenesis in liver. We administered several 
chemical inhibitors targeting the HCC signaling pathways including MAPK pathway, 
JAK/STAT pathway, PI3K pathway and cMyc transcription factor, in the two 
transgenic larval zebrafish. We initially assessed the morphological change in liver 
size by quantification analysis and further we confirmed the inhibition effects by 
analyzing the cell proliferation in the treated fish liver. Our findings include: 
1) By employing the ImageJ program to analyze the images, we developed a 
sensitive and simple way for evaluating the chemical effects in larval fish, 
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complementing the advantages of transgenic approach and transparency of 
zebrafish larvae, and overcoming the problem that some delicate 
morphological alterations that are not easy to be distinguished by direct visual 
examination. 
2) Stat5 inhibitor (Stat5In) significantly inhibited liver hyperplasia in induced 
cMyc and kras fish, suggesting that JAK/STAT pathway participate in both 
cMyc-mediated and kras-mediated tumor development and targeting this 
pathway is helpful to delay and hinder tumor growth.  
3) MEK1/2 inhibitor PD0325901 significantly inhibited liver hyperplasia in both 
induced cMyc and kras fish. Unlike PD0325901, U0126 stimulated liver 
overgrowth in normal fish. Consequently, we found that U0126 only 
significantly inhibited liver overgrowth in kras fish but not in cMyc fish. The 
contradictory role of U0126 in promoting normal liver growth and potential 
suppression of induced liver hyperplasia requires further investigation. 
4) The PI3K inhibitor LY294002 was able to hinder the liver overgrowth in 
treated cMyc fish but not in treated kras fish, indicating that PI3K pathway, 
which reflects angiogenesis, a hall mark of cancer, is a more striking event in 
cMyc driven oncogenesis than kras driven carcinogenesis and thus anti-
angiogenesis is more effective in cMyc-mediated tumorigenesis. 
5) 10058-F4, a specific inhibitor of cMyc, showed no obvious inhibition effect in 
both cMyc and kras fish, which might indicate that higher concentration of this 
inhibitor is needed to achieve better inhibition effect, and targeting cMyc in 
kras driven oncogenesis may not be fully effective.  
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6) Based on the above analysis, these two inducible tumor lines share common 
signaling pathways during early HCC tumor initiation though difference exists 
in determining which pathway is the leading role. 
Collectively, we have proved that larval zebrafish systems are ideal for 
chemical screening in preclinical drug discovery for liver cancer. And we have 
confidence in believing that our two inducible zebrafish models are suitable 
for further studying and delineating the respective signaling pathways in cMyc 
driven and kras driven liver oncogenesis.  
The limitations of this study include insufficient evidences to demonstrate the 
inhibition mechanism, e.g. lacking of information such as apoptosis analysis, 
the protein or mRNA level of the targeted molecules or downstream effectors. 
In consequence, further study need to be carried out to fill in this gap. 
4.4 Prospects 
 
From above analysis, it seems that sometimes targeting only one pathway is 
not so efficacious. 10058-F4 targeting cMyc transcription factor in kras fish and 
U0126 targeting MEK1/2 in cMyc fish both failed to inhibit tumor growth, it might be 
possible that if combining 10058-F4 with U0126 in kras fish or cMyc fish, the result 
would be different. In fact, there is a strong therapeutic rationale for attempting to 
inhibit several important signaling pathways simultaneously in patients with HCC. It 
was found that PKI-587 a highly potent dual PI3K/mTOR kinase inhibitor was able to 
enhance antitumor efficacy when combined with PD0325901 (Mallon et al., 2011). 
Therefore, simultaneous inhibition of both the MAPK pathway and the PI3K pathway 
may also offer therapeutic advantages over inhibiting either pathway alone. Thus 
using different inhibitors targeting different pathways may yield better effect and may 
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be useful to develop a cocktail approach for anti-cancer drug discovery. Preliminary 
data about the suppression of induced liver hyperplasia by chemical inhibitors were 
obtained and the next step is to look into the underlying mechanism of this inhibition. 
It is very intriguing to perform western blots to examine the proteins level of the 
targeting genes and their downstream effectors, which may help to validate the 
inhibition mechanism and to reveal novel perturbed protein during tumorigenesis. 
More compounds targeting specific signaling pathways will be identified for 
cancer treatment in the future. For example, FGF signaling pathway and Wnt pathway 
are of great interest to us, and SU5402 and IWR-1 have been reported to target these 
two pathways respectively; hence, in the near future, we would like to test these two 
inhibitors on our transgenic zebrafish. 
It is very interesting to include xmrk fish, where liver carcinogenesis is driven 
by xmrk overexpression (Li et al., 2012), in our study to apply the same inhibitors as 
those in cMyc and kras fish, so that we can get more and comprehensive 
understanding about the HCC progression in different genetic background. By 
crossing our existing tumor lines, kras, cMyc and xmrk fish for further study, we 
expect to see that there are conserved signaling pathways existing in all liver cancers, 
and targeting the common signaling pathways can be a promising strategy for anti-
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